Subcutaneous pulsatile glucocorticoid replacement therapy

Georgina M. Russell*, Claire Durant*, Alia Ataya†, Chrysoula Papastathi*, Ragini Bhake*, Wolfram Woltersdorf‡ and Stafford Lightman*

*Henry Wellcome Laboratories for Integrative Neurosciences and Endocrinology, Dorothy Hodgkin Building, University of Bristol, †School of experimental psychology, University of Bristol, and ‡Department of Clinical Biochemistry, UHBristol, Bristol, UK

Summary

The glucocorticoid hormone cortisol is released in pulses resulting in a complex and dynamic ultradian rhythm of plasma cortisol that underlies the classical circadian rhythm. These oscillating levels are also seen at the level of tissues such as the brain and trigger pulses of gene activation and downstream signalling. Different patterns of glucocorticoid presentation (constant vs pulsatile) result not only in different patterns of gene regulation but also in different neuroendocrine and behavioural responses. Current ‘optimal’ glucocorticoid replacement therapy results in smooth hormone blood levels and does not replicate physiological pulsatile cortisol secretion. Validation of a novel portable pulsatile continuous subcutaneous delivery system in healthy volunteers under dexamethasone and metyrapone suppression. Pulsatile subcutaneous hydrocortisone more closely replicates physiological circadian and ultradian rhythmicity.

Introduction

The hypothalamic–pituitary–adrenal (HPA) axis is characterized by a circadian rhythm underpinned by a dynamic ultradian rhythm comprising discrete pulses of adrenocorticotropic hormone (ACTH) and glucocorticoid secretion in all mammalian species studied. In man, deconvolution analysis has revealed secretory pulses of cortisol every 80–110 min, which are reflected in the plasma with cortisol peaks approximately every 3 h. This HPA activity is tightly controlled via a feedforward/feedback system with natural inbuilt delays via signalling within the pituitary and adrenal glands with ACTH pulsatility being absolutely critical for normal adrenal function. Individual pulses of glucocorticoid are transmitted to the tissues and provide an oscillating signal at the cellular level. Pulses of corticosterone/cortisol induce a pulse of glucocorticoid receptor (GR) binding that then triggers cyclic GR-mediated transcriptional regulation or gene pulsing. This is seen in cultured cells and animal models. Indeed, the same dose of glucocorticoid (constant or pulsatile) results not only in different patterns of gene regulation but also in differing neuroendocrine and behavioural responses. This implies that differential responsiveness of central nervous system’s stress reactivity is dependent upon the pattern of glucocorticoid presentation.

Cortisol is an anticipatory hormone, and its levels start to rise first thing in the morning prior to awakening. Therapeutically, we treat patients requiring glucocorticoid replacement therapy with two or three times daily oral replacement regimes in an attempt to mimic their circadian cortisol rhythm. This has certain limitations; patients must wake up with very low cortisol levels and then take their morning dose of hydrocortisone. Hence, they have a shifted curve with their morning peaks occurring after they wake. Additionally, standard oral replacement produces smooth hormone levels and fails to address the underlying pulsatile ultradian rhythm. Despite our best efforts to provide optimal therapy and our success in preventing deaths from severe corticosteroid deficiency, mortality rates stubbornly remain double that of the background population—a risk similar to smoking. This is predominantly due to an increased incidence of cancer, cardiovascular and infectious disease. Patients also report poor health-related quality of life especially mental and physical fatigue. Of these, morning fatigue is particularly challenging. Reports show patients receiving three rather than twice-daily hydrocortisone have higher quality of life suggesting the pattern of steroid replacement is important. To overcome the problems assumed to be related to the pattern of cortisol replacement, we have developed a pulsatile glucocorticoid delivery system that more closely replicates normal physiology.

Materials and methods

Local ethical and institutional approval was obtained. The study was discussed with the Medicines and Healthcare Products Regulatory Authority, and formal approval was deemed unnecessary. The study was conducted according to the principles of Good
Clinical Practice and the Declaration of Helsinki. Preliminary studies were carried out on 23 healthy volunteers (7 females, 16 males) including (i) dose ranging of individual pulses, (ii) testing for optimal frequency of pulses to ensure appropriate peak and nadir levels throughout the day and (iii) combination of three different pulse doses over the 24 h to reproduce normal circadian and ultradian rhythmicity.

**Infusion pump**

A portable subcutaneous infusion pump (Crono P, CANE Applied Medical Technology Ltd, Cambridge, UK) containing 100 mg of hydrocortisone in 1 ml (efortesol®; Sovereign, Essex UK) was made up to 10 ml with 0.9% saline and preprogrammed to deliver a high-, medium- and low-sized pulse of hydrocortisone. All pulses were delivered at a flow rate of 10 μl/s. The pump delivered hydrocortisone subcutaneously via a cannula (Medtronic quick-set®, Medtronic MiniMed, Northridge, CA, USA) inserted into the abdominal subcutaneous tissue.

**Blood sampling**

A venous cannula was also inserted in the antecubital fossa of the arm for 10-minutely blood sampling via the human automated blood sampling system (HABS).2 Blood samples were taken for cortisol every 10 min and ACTH every hour. During the blood sampling period, a standardized routine was adhered to.

**Experimental protocol**

Experiments 1 and 2 were performed to establish the dose range and frequency of individual pulses of hydrocortisone. 21 healthy volunteers (7 females, 14 males) underwent dexamethasone suppression. 1 mg of dexamethasone was taken at midnight at home; a further 1 mg was taken at 9 a.m. at the research unit. Volunteers received two doses of hydrocortisone at varying time intervals (dose range 0.3–4 mg) over a 7-h period. Blood samples were taken 09:30–16:30.

Experiment 3a. A healthy male volunteer underwent dexamethasone suppression. 1 mg of dexamethasone was taken at 08:00 at home on day 1. A further 1 mg of dexamethasone was taken at 12:00, 1 mg at 18:00, 0.5 mg at 24:00 and 0.5 mg at 07:00 the following morning (day 2) at the research unit. The volunteer received a pulse of hydrocortisone via the pump every 3 h, starting with a high dose of 400 μg (4 mg) at 12:00, 15:00 and 18:00, a medium dose of 230 μg (2.3 mg) at 21:00, 24:00 and 03:00 and a low dose of 50 μg (0.5 mg) at 06:00 and 09:00 to give a total daily dose of 19.9 mg of hydrocortisone. Blood sampling commenced at 12:00 and finished at 12:00 the following day.

Experiment 3b. In this study, endogenous cortisol synthesis was inhibited in a healthy male volunteer with metyrapone. A starting dose of 250 mg tds was used, increasing by 250 mg tds every 1–2 days to 750 mg tds over 5 days. Metyrapone was taken at meal times to increase compliance and decrease gastric side effects. Hydrocortisone replacement therapy was again administered via the infusion pump using a high dose of 400 μl (4 mg) at 03:00, 06:00 and 09:00, a medium dose of 230 μl (2.3 mg) at 12:00, 15:00 and 18:00 and a low dose of 50 μl (0.5 mg) at 21:00 and 00:00 to give a total daily dose of 19.9 mg of hydrocortisone. After being attached to the pump, the volunteer underwent his usual daily routines. The line and syringe were changed on day 3 according to manufacturer’s guidelines. This was performed at a location convenient to the volunteer. On day 4, he attended the research unit blood sampling commenced at 15:00 and finished at 15:00 the following day.

**Assays**

Cortisol samples were allowed to clot at room temperature prior to centrifugation, and serum was frozen at −80°C until assayed. Samples for ACTH were collected in chilled EDTA tubes and kept on ice until centrifugation at 4°C within 30 min. Plasma was stored at −80°C until assayed. Analysis was performed by the department of clinical biochemistry at the University Hospitals of Bristol NHS Foundation Trust (UHBrstol) using an electrochemiluminescence immunoassay (Cobas®; Roche, Indianapolis, IN, USA). Cross-reactivity with 11-deoxycortisol was 4.1%.

**Results**

Figure 1 shows the dose response of plasma cortisol to different doses of subcutaneous cortisol in dexamethasone-suppressed volunteers. A high pulse size of 4 mg, medium 2.3 mg and low 0.5 mg was chosen. A pulse frequency of 3 h was chosen as at a higher frequency, there was an accumulation effect between pulses and the definitive on/off pattern of the pulse lost (data not shown). Fig. 2 shows the 24 h profile of plasma cortisol utilizing our infusion paradigm under dexamethasone suppression (for practical reasons, timing of pulses was not synchronized to chronological time). A circadian peak of >500 nm and trough of <100 nm of cortisol were achieved; clear individual pulses of cortisol can be seen. This is combined with appropriate ACTH suppression confirming dexamethasone suppression of endogenous cortisol production. These results were confirmed in a separate study in which instead of dexamethasone inhibition of ACTH secretion, secretion of cortisol was suppressed with metyrapone. In this paradigm, our protocol of pulsatile hydrocortisone replacement therapy in fig. 3 shows the 24 h profile of plasma cortisol. A circadian peak of >500 nm and trough of <100 nm of cortisol were achieved. Clear individual pulses of cortisol can be seen. This is combined with appropriate ACTH concentrations confirming that despite inhibition of endogenous cortisol synthesis, our infused cortisol maintained normal physiological ACTH levels.

**Discussion**

The HPA axis is characterized by a circadian peak of cortisol at about 09:00 of >500 nm and a trough at midnight of
Standard oral hydrocortisone replacement therapy usually splits the medication dose into three or even four times a day in an attempt to mimic the circadian pattern of release. This is clearly more advantageous than once/twice daily; however there is some evidence that increasing the frequency of oral replacement alters nadir levels. Plenadren® modified-release hydrocortisone, Chronocort® and constant subcutaneous hydrocortisone infusions have been developed to improve the circadian pattern of cortisol replacement. None of these regimens, however, take into account the true physiological pattern.

Fig. 1 Plasma cortisol dose-response curves ± SEM to 4 mg (n = 8), 3·5 mg (n = 2), 2·3 mg (n = 4), 1·5 mg (n = 2), 0·5 mg (n = 4), 0·3 mg (n = 3) doses of subcutaneous hydrocortisone expressed as change in cortisol from baseline in dexamethasone-suppressed healthy volunteers.

<100 nm. Standard oral hydrocortisone replacement therapy usually splits the medication dose into three or even four times a day in an attempt to mimic the circadian pattern of release. This is clearly more advantageous than once/twice daily; however there is some evidence that increasing the frequency of oral replacement alters nadir levels. Plenadren® modified-release hydrocortisone, Chronocort® and constant subcutaneous hydrocortisone infusions have been developed to improve the circadian pattern of cortisol replacement. None of these regimens, however, take into account the true physiological pattern.

Fig. 2 24-h cortisol (10 minutely) and ACTH (hourly) profiles in a dexamethasone-suppressed healthy male volunteer receiving hydrocortisone (total daily dose 19·9 mg) via a pulsatile portable subcutaneous infusion pump.

© 2014 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
of cortisol secretion which occurs in individual pulses with a mathematically modelled mean interburst interval of 80–110 min and plasma peaks and troughs approximately every 3 h. In vitro and in vivo work has shown that these pulses of glucocorticoid in the blood are also seen at the tissue level and induce a phenomenon known as gene pulsing. A pulse of glucocorticoid triggers a pulse of glucocorticoid receptor binding which then triggers a pulse of downstream activity. This is highly specific to natural (cortisol and corticosterone) as opposed to synthetic glucocorticoids. There is very clear evidence from animal models that oscillating levels of corticosterone are vital for normal cognitive function. Indeed, the pattern of glucocorticoid exposure – and even the phase of the pulse – results in differential effects on behaviour and the c-fos response of the brain – particularly the amygdala – to a stressor. This is also likely to lead to metabolic and cardiovascular dysfunction. Current replacement regimes with their relatively constant glucocorticoid receptor occupancy and consequent abnormal glucocorticoid-dependent gene transcription undoubtedly contribute to glucocorticoid side effects and may even be a causal factor for the excessive morbidity and mortality of patients on glucocorticoid replacement.

The current report shows that it is possible to reproduce near physiological patterns of both circadian and ultradian rhythmicity using a specialized pump and simple subcutaneous infusion techniques. A cortisol circadian peak of 500 nm with a trough of <100 nm in combination with discrete pulses of cortisol was achieved, similar to healthy volunteer data using the same analytical technique. The pump was well tolerated by volunteers with no irritation or infections reported. Physiological cortisol production is approximately 8–12 mg/day whilst patients typically receive 20 mg a day. In this study, a standard patient dose was chosen as we needed proof of concept that it is possible to replicate a physiological pattern of replacement and safety had to be of foremost importance. We are now in a position not only to assess optimal dose but also to use this equipment in controlled clinical trials to assess the cognitive, metabolic, cardiovascular and immunological importance of normal physiological patterns of cortisol in patients on steroid replacement.

Acknowledgement

We would like to thank Miss Kirsty Stevenson, Department of Clinical Chemistry, UHBristol, and Mr Ray Morrissey at Applied Medical Technology. This work was funded by the Medical Research Council and the Wellcome Trust.

Conflict of interest

Nothing to declare.

References

1 Lightman, S.L., Wiles, C.C., Atkinson, H.C. et al. (2008) The significance of glucocorticoid pulsatility. European journal of pharmacology, 583, 255–262.
2 Veldhuis, J., Iranmanesh, A., Lizarralde, G. et al. (1989) Amplitude modulation of a burstlike mode of cortisol secretion subserves the circadian glucocorticoid rhythm. The American Journal of Physiology- Endocrinology And Metabolism, 257, E6.
3 Follenius, M., Simon, C., Brandenberger, G. et al. (1987) Ultradian plasma corticotropin and cortisol rhythms: time-series analyses. Journal of endocrinological investigation, 10, 261–266.
4 Lightman, S., Terry, J. (2014) The importance of dynamic signalling for endocrine regulation and drug development: relevance for glucocorticoid hormones. The Lancet Diabetes & Endocrinology. Epub 18/02/2014 doi:10.1016/S2213-8587(13)70182-7.
5 Henley, D.E., Leendertz, J.A., Russell, G.M. et al. (2009) Development of an automated blood sampling system for use in humans. Journal of medical engineering & technology, 33, 1–10.
6 Walker, J.J., Terry, J.R. & Lightman, S.L. (2010) Origin of ultradian pulsatility in the hypothalamic-pituitary-adrenal axis. *Proceedings*, 277, 1627–1633. PubMed PMID: 20129987. eng.

7 Spiga, F., Waite, E.J., Liu, Y. et al. (2011) ACTH-dependent ultradian rhythm of corticosterone secretion. *Endocrinology*, 152, 1448–1457. PubMed PMID: 21303943. eng.

8 Bhake, R.C., Leendertz, J.A., Linthorst, A.C. et al. (2013) Automated 24-hours sampling of subcutaneous tissue free cortisol in humans. *Journal of medical engineering & technology*, 37, 180–184. PubMed PMID: 23547774.

9 Stavreva, D.A., Wiench, M., John, S. et al. (2009) Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. *Nature Cell Biology*, 11, 1093–1102. PubMed PMID: 19684579. Epub 2009/08/18. eng.

10 Sarabdjitsingh, R.A., Conway-Campbell, B.L., Leggett, J.D. et al. (2011) Stress responsiveness varies over the ultradian glucocorticoid cycle in a brain-region-specific manner. *Endocrinology*, 151, 5369–5379. PubMed PMID: 20861228. eng.

11 Crown, A. & Lightman, S.L. (2005) Why is the management of glucocorticoid deficiency still controversial: a review of the literature. *Clinical endocrinology*, 63, 483–492.

12 Scott, R.S., Donald, R.A. & Espiner, E.A. (1978) Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy. *Clinical endocrinology*, 9, 571–576. PubMed PMID: 218754.

13 Bergthorsdottir, R., Leonsson-Zachrisson, M., Anders, O. et al. (2006) Premature mortality in patients with Addison’s disease: a population-based study. *The Journal of Clinical Endocrinology & Metabolism*, 91, 4849–4853.

14 Bleicken, B., Hahner, S., Loeffler, M. et al. (2008) Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. *European Journal of Endocrinology*, 159, 811–817.

15 Groves, R.W., Toms, G.C., Houghton, B.J. et al. (1988) Corticosteroid replacement therapy: twice or thrice daily? *Journal of the royal society of medicine*, 81, 514–516.

16 Barbetta, L., Dall’Asta, C., Re, T. et al. (2005) Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism. *Journal of endocrinological investigation*, 28, 632–637.

17 Johannsson, G., Nilsson, A.G., Bergthorsdottir, R. et al. (2012) Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. *The Journal of clinical endocrinology and metabolism*, 97, 473–481. PubMed PMID: 22112807.

18 Verma, S., VanRyzin, C., Sinaii, N. et al. (2010) A pharmacokinetic and pharmacodynamic study of delayed-and extended-release hydrocortisone (ChronocortTM) vs. conventional hydrocortisone (CortefTM) in the treatment of congenital adrenal hyperplasia. *Clinical endocrinology*, 72, 441–447.

19 Oksnes, M., Bjornsdottir, S., Isaksson, M. et al. (2014) Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison’s disease: a randomized clinical trial. *The Journal of clinical endocrinology and metabolism*. Epub 02/11/2014. jc20134253.

20 Lightman, S.L. & Conway-Campbell, B.L. (2010) The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration. *Nature reviews*, 11, 710–718. PubMed PMID: 20842176. eng.

21 Henley, D.E., Lightman, S. (2014) Cardio-metabolic consequences of glucocorticoid replacement: relevance of ultradian signalling. *Clinical endocrinology*, 80, 621–628. | DOI: 10.1111/cen.12422014.

22 Henley, D.E., Russell, G.M., Douthwaite, J.A. et al. (2009) Hypothalamic-pituitary-adrenal axis activation in obstructive sleep apnea: the effect of continuous positive airway pressure therapy. *The Journal of clinical endocrinology and metabolism*, 94, 4234–4242. PubMed PMID: 19820009. eng.

23 Kumari, M., Shipley, M., Stafford, M. et al. (2011) Association of diurnal patterns in salivary cortisol with all-cause and cardiovascular mortality: findings from the Whitehall II study. *The Journal of clinical endocrinology and metabolism*, 96, 1478–1485. PubMed PMID: 21346074. Pubmed Central PMCID: 3085201.

24 Russell, G.M., Henley, D.E., Leendertz, J. et al. (2011) Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. *Journal of Neuroscience*, 30, 6106–6115. PubMed PMID: 20427668. eng.

25 Debono, M., Ross, R.J. & Newell-Price, J. (2009) Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. *European Journal of Endocrinology*, 160, 719–729.

26 Kerrigan, J.R., Veldhuis, J.D., Leyo, S.A. et al. (1993) Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. *The Journal of clinical endocrinology and metabolism*, 76, 1505–1510. PubMed PMID: 8501158. eng.